Skip to NavigationSkip to content

Alvotech recruit new CEO from within

Published on: 09/08/17

Alvotech, a biopharmaceutical company focusing on the development and manufacture of based in Reykjavik, Iceland, has replaced outgoing CEO, Eef Schimmelpennink, with Rasmus Rojkjaer. The company has only existed since 2013, after being spun out of Alvogen, and Rojkjaer has only recently joined the company.

Rojkjaer has been with Alvotech since 2016, and previously performed the role of Chief Operating Officer. Before his time at Alvotech, Rojkjaer had plenty of experience working at Novo Nordisk, as a Senior Director, and as Chairman of the Board at Mylan.

He is tasked with creating a global market leader in biogenerics through the development of high quality and cost-controlled biosimilar products. He will be expected to tap into his experience with Mylan for this project, where he created and led the establishment of its biosimilar strategy. Rojkjaer will also join the executive board at Alvogen.

Robert Wessman, Alvotech’s Chairman and founder, said: “Rasmus has been an integral part of Alvotech‘s management team since joining us in 2016 as Chief Operating Officer, and we are fortunate to have someone with his experience to lead our biosimilar business going forward. The company has achieved many important milestones since its launch in 2013. Now, as Alvotech enters the next phase, Eef will be leaving to take on new ventures. On behalf of the Board and management team, I would like to thank Eef for his contributions to Alvotech.”

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches